SCHEDULE: Soleus Capital Boosts NovoCure Stake to 6.2%
Beneficial Ownership Report
Soleus Capital Master Fund and its affiliates have disclosed a 6.2% beneficial ownership stake in NovoCure Limited, holding 6,904,302 ordinary shares.
Summary
- Soleus Capital Master Fund, L.P., along with its affiliates Soleus Capital, LLC, Soleus Capital Group, LLC, Soleus Capital Management, L.P., Soleus GP, LLC, and Guy Levy, collectively reported beneficial ownership of 6,904,302 ordinary shares of NovoCure Limited.
- This aggregate amount represents 6.2% of NovoCure Limited's outstanding ordinary shares.
- The percentage is calculated based on 111,799,290 ordinary shares outstanding as of July 18, 2025, as reported in NovoCure's Quarterly Report on Form 10-Q filed on July 24, 2025.
- The reporting persons hold shared voting power and shared dispositive power over all 6,904,302 shares, with no sole voting or dispositive power.
- The filing is an Amendment No. 1 to a Schedule 13G, indicating a change in previously reported beneficial ownership.
Sentiment
Score: 5
Explanation: The filing is a factual disclosure of beneficial ownership, providing neutral information without inherent positive or negative sentiment regarding company performance or outlook.
Future Outlook
NA
Industry Context
This filing reflects a significant institutional investor's position in NovoCure Limited, a company known for its innovative medical devices, particularly in oncology. Such disclosures provide transparency regarding major ownership stakes, which can influence market perception and investor confidence within the healthcare and medical technology sectors.
Stakeholder Impact
- Shareholders: Provides transparency regarding a significant institutional investor's stake, which can influence market sentiment and potentially signal confidence or strategic interest in the company.
Key Dates
| Date | Description |
|---|---|
| 06/30/2025 | Date of event which required the filing of this statement. |
| 07/18/2025 | Date as of which NovoCure Limited's ordinary shares outstanding were calculated (111,799,290 shares). |
| 07/24/2025 | Date NovoCure Limited's Quarterly Report on Form 10-Q was filed, providing the shares outstanding figure. |
| 08/05/2025 | Date the Schedule 13G Amendment No. 1 was signed and filed. |
Keywords
NovoCure Limited, Soleus Capital, Beneficial Ownership, SEC Filing, Schedule 13G, Institutional Investor, Equity Stake, G6674U108
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.